{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T10:10:44Z","timestamp":1783937444956,"version":"3.55.0"},"reference-count":0,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2000,1,1]],"date-time":"2000-01-01T00:00:00Z","timestamp":946684800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Sarcoma"],"published-print":{"date-parts":[[2003,1]]},"abstract":"<jats:p><jats:italic>Purpose<\/jats:italic>: The purpose of our study is to retrospectively review our institutional experience with adult rhabdomyosarcoma (RMS) to determine presentation, prognostic factors and patterns of failure in this disease.<\/jats:p><jats:p><jats:italic>Materials and Methods<\/jats:italic>: All patients \u2265 16 years with a diagnosis of rhabdomyosarcoma were retrospectively reviewed. Tumors were classified according to the Intergroup Rhabdomyosarcoma Study (IRS) staging and grouping system. Median follow\u2010up for surviving patients was 12.5 years.<\/jats:p><jats:p><jats:italic>Results:<\/jats:italic> A total of 39 patients (23 male, 16 female) were seen at our institution from 1961 to 1999. Median age was 45 years,\nand age distribution showed a bimodal peak at the late teens to twenties and later in the sixties. Tumor in the extremity was\nmost common as seen in 15 (39%); this was followed by head and neck in 11 (28%), genitourinary in eight (20%), trunk\/retroperitoneum in four (10%) and other in one (3%). Tumor stage was T1 in 21 (52%) while 26 (67%) were &gt; 5 cm in size.\nPleomorphic histology was most common (36%) and increased in incidence according to age category: 0% for ages 16\u201319,\n27% for ages 20\u201349 and 60% for ages \u2265 50 years old (<jats:italic>P<\/jats:italic> &lt; 0.01). The median survival for the entire population was 2.25 years\nwith a 5\u2010year overall survival rate of 35%. Multivariate analysis identified early IRS stage (<jats:italic>P<\/jats:italic> &lt; 0.001), non\u2010embryonal\nhistology (<jats:italic>P<\/jats:italic> &lt; 0.009), favorable site (<jats:italic>P<\/jats:italic> = 0.024), female gender (<jats:italic>P<\/jats:italic> = 0.034), early T\u2010stage (<jats:italic>P<\/jats:italic> = 0.034) and absence of nodal\nmetastases (<jats:italic>P<\/jats:italic> = 0.037) as predictors of a better survival. The 5\u2010year progression\u2010free survival rate was 21%. Female gender\n(<jats:italic>P<\/jats:italic> = 0.002), non\u2010embryonal histology (<jats:italic>P<\/jats:italic> = 0.009), early IRS stage (<jats:italic>P<\/jats:italic> = 0.02) and early T stage (<jats:italic>P<\/jats:italic> = 0.033) were found on\nmultivariate analysis to predict for improved progression\u2010free survival. The 5\u2010year local control rate was 51%, and\nmultivariate analysis found that only early T\u2010stage was predictive of better local control (<jats:italic>P<\/jats:italic> = 0.045). Five of six Group II\npatients and five of eight Group III patients who received radiotherapy (RT) were locally controlled. Only one of five Group\nIII patients was locally controlled without RT.<\/jats:p><jats:p><jats:italic>Conclusions:<\/jats:italic> The overall prognosis of adult RMS is worse than reported in children, but age criteria within the adult\npopulation did not further classify outcome. RT is an effective local modality providing local control in almost all Group II\nand majority of Group III patients.<\/jats:p>","DOI":"10.1080\/1357714031000114147","type":"journal-article","created":{"date-parts":[[2003,11,11]],"date-time":"2003-11-11T16:23:59Z","timestamp":1068567839000},"page":"1-7","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Presentation, Prognostic Factors and Patterns of Failure in Adult Rhabdomyosarcoma"],"prefix":"10.1155","volume":"7","author":[{"given":"James H.","family":"Simon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold C.","family":"Paulino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine M.","family":"Ritchie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina A.","family":"Mayr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Buatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2003,1]]},"container-title":["Sarcoma"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/journals\/sarcoma\/2003\/150381.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1080\/1357714031000114147","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T04:14:38Z","timestamp":1723090478000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1080\/1357714031000114147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,1]]},"references-count":0,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2003,1]]}},"alternative-id":["10.1080\/1357714031000114147"],"URL":"https:\/\/doi.org\/10.1080\/1357714031000114147","archive":["Portico"],"relation":{},"ISSN":["1357-714X","1369-1643"],"issn-type":[{"value":"1357-714X","type":"print"},{"value":"1369-1643","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,1]]},"assertion":[{"value":"2003-01-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}